Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1006
- Registration Number
- NCT02783729
- Locations
- 🇺🇸
Saint Francis Sleep Allergy and Lung Institute, Clearwater, Florida, United States
🇨🇦Toronto Sleep Institute, Toronto, Ontario, Canada
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT02753595
Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT02736162
Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02723630
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 241
- Registration Number
- NCT02702388
- Locations
- 🇮🇹
Facility #6, Milano, Italy
🇰🇷Facility#1, Busan, Korea, Republic of
🇦🇺Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02686164
- Locations
- 🇺🇸
Facility # 1, San Antonio, Texas, United States
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT02657369
Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02583451
- Locations
- 🇳🇱
Maastricht University, Maastricht, Netherlands
A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02578316
Study of E7046 in Subjects With Selected Advanced Malignancies
- First Posted Date
- 2015-09-03
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02540291
© Copyright 2024. All Rights Reserved by MedPath